Changing of HCV clade pattern in Iran; The possible means for something good

Hepatitis Monthly

Volumn 14, Issue 1, 2014, Pages

  Afzal, Muhammad Sohail ^a   Anjum, Sadia ^a   Zaidi, Najam us Sahar Sadaf ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Genotype; Hepatitis C; Iran; Prevalence; Therapeutics

Indexed keywords

ALPHA2B INTERFERON PLUS RIBAVIRIN;

CLADISTICS; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 3A; HUMAN; IMMUNE SYSTEM; IRAN; LETTER; PREVALENCE; VIRUS INFECTION;

EID: 84892571707     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.11879     Document Type: Letter

References (8)

1. Anjum S, Ali S, Ahmad T, Afzal MS, Waheed Y, Shafi T, et al. Sequence and structural analysis of 3' untranslated region of hepatitis C virus, genotype 3a, from pakistani isolates. Hepat Mon. 2013;13(5):e8390.
2. Shakeri MT, Nomani H, Ghayour Mobarhan M, Sima HR, Gerayli S, Shahbazi S, et al. The prevalence of hepatitis C virus in mashhad, iran: a population-based study. Hepat Mon. 2013;13(3):e7723.
3. Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon. 2013;13(1):e7991.
4. Waheed Y, Saeed U, Anjum S, Afzal MS, Ashraf M. Development of Global Consensus Sequence and Analysis of Highly Conserved Domains of the HCV NS5B Prote in. Hepat Mon. 2012;12(9):e6142.
5. Al-Kubaisy WA, Niazi AD, Kubba K. History of miscarriage as a risk factor for hepatitis C virus infection in pregnant Iraqi women. East Mediterr Health J. 2002;8(2-3):239-44.
6. Aktas E, Ogedey ED, Kulah C, Begendik Comert F. [Hepatitis C virus genotypes in a province of western Black-Sea region, Turkey]. Mikrobiyol Bul. 2010;44(4):647-50.
7. Afzal MS. Comparison of HCV prevalence in Pakistan and Iran, An Insight into Future. Hepat Mon. 2013;13(12):[Epub ehead of print].
8. Kim HI, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW, et al. Treatment Response and Tolerability of Pegylated Interferon-alpha Plus Ribavirin Combination Therapy in elderly Patients (≥ 65 years) With Chronic Hepatitis C in Korea. Hepat Mon. 2012;12(7):430-6.